AFMD News and Press, Affimed N.V. From 04/17/23

The poster presentation highlights the relevance of CD16A shedding for serial killing by AFM13-engaged natural killer (NK) cells It demonstrates the potential of AFM13 to induce serial killing, even in tumor cells with low target expression HEIDELBERG, Germany, April 17, 2023 (GLOBE NEW...

AFM13 demonstrated robust activity on the primary end point with an objective response rate (ORR) of 32.4% and 10.2% complete response rate (CR) in Intent to Treat (ITT) population Patients with Angioimmunoblastic T cell lymphoma (AITL), one of the most frequent subtypes of peripheral ...

2023-04-06 16:36:07 ET Affimed ( NASDAQ: AFMD ) said it had received a non-compliance notice from the Nasdaq stating that the bid price of its shares had closed below the minimum $1 per share requirement for continued listing. The company has 180 days, or until Octob...

HEIDELBERG, Germany, April 06, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 4, ...

2023-03-29 06:51:32 ET Affimed ( NASDAQ: AFMD ) said the first patient was dosed in a phase 1 trial of AFM28 monotherapy to treat patients with CD123-positive relapsed/refractory (r/r) acute myeloid leukemia (AML). "AFM28 broadens our footprint in hematological malignancie...

HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that the first patient was dosed in a phase 1 multicenter, open label, first-in-hum...

2023-03-23 15:04:05 ET Affimed N.V. (AFMD) Q4 2022 Earnings Conference Call March 23, 2023 08:30 ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith ...

2023-03-23 13:37:42 ET German biotech Affimed ( NASDAQ: AFMD ) fell ~7% on Thursday to reach a new 52-week low after announcing financials for 2022, along with a few updates on its clinical programs. The cancer drug developer lost a third of its value in December after a...

2023-03-23 06:32:32 ET Affimed press release ( NASDAQ: AFMD ): Q4 GAAP EPS of -€0.60. Revenue of €41.35M (+2.4% Y/Y). As of December 31, 2022, cash and cash equivalents were €190.3M, with an anticipated cash runway into 2025. For further...

AFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023 AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meeting AFM24: Data from the three ongoing studies expected to be presented at scientific conferences i...